1300 Understanding the China IP Landscape of 2010 ¨C a Roadmap for the Pharmaceutical Industry 1430 Coffee Break 1500 Winning Patent Litigation Strategies for China 1600 Panel Discussion: To Win or to Lose? ¨CLeveraging the Timing and Scope in the Filing Strategy to Gain Best ROI on Intangible Assets
DAY ONE / Thursday, May 20
0800 Registration 0830 Welcome Address from the Organizing Committee
0845 Chairperson¡¯s Opening Remarks
0900 Basic Medicine System Meet with the Industry: Status Quo of Pharmaceutical Industry in the Reform 0930 Pharmaceutical Enterprises¡¯ Status and Prospect: Under the Reform Wave 1000 Unveiling the Procedure and Guidelines for New Drug Registration
1030 Coffee Break 1100 Quality Standards and Public Health - USP Perspective 1130 Developing Medicine with Self-owned Intellectual Property Rights: Reviewing the Status Quo of New Drug R&D in China
1230 Luncheon
1400 Open Innovation in Diversified Healthcare Business 1430 Today¡¯s Merck: External Discovery and Preclinical Sciences 1500 Registration of Nonprescription Drugs in North America & Potential Influence on Nonprescription Regulatory Trends in China 1530 Coffee Break 1600 Big Pharma¡¯s R&D in China: Current Status and Future Directions
1630 Risks and Challenges of a Local Pharmaceutical Company Facing the Reform: Strategy Adjustment Issues 1700 Roche Partnering Asia: In Search of Innovation 1730 Panel Discussion: How Does Industry Players Collaborate in Vaccine R&D?
1800 Chairperson¡¯s Closing Remarks 1830 Cocktail Party
0900 Delivering Success Together: Pharmaceutical R&D Partnering for Emerging Markets 0930 Filling Up the Gap between Drug Innovation and Production Line by Collaborating with Biotech Companies 1000 Improving Pharma-CRO Efficiency Through Technology Enablement 1030 Coffee Break 1100 Big Pharma¡¯s Perspective: Capturing Emerging Opportunities through R&D Partnerships 1130 Development and Opportunities of Biotechnology in South East Asia 1200 Panel Discussion: Big Pharmas, CROs and Biotechs Benefit From Pharmaceutical Moving Up the Value Chain
1230 Luncheon
1400 Pioneering Personalized Healthcare through Pharma Partnering: A Case Study in Companion Diagnostic
1500 Setting up Biomarker and Translational Medicine Research Collaborations in China 1530 Coffee Break 1600 Building Clinical Development Centers in Pharmas and Academia for Global Clinical Trials 1630 Panel Discussion: Status, Prospect, and Challenges of Discovery and Preclinical CROs in China 1700 Panel Discussion: Finding the Value Proposition of Increasing Cooperations in Clinical R&D
1730 Chairperson¡¯s Closing Remarks 1800 End of the Conference
Event Overview 
